From preclinical evidence to human studies: what makes a drug candidate ready for a First-in-Human trial
I personally would not recommend to our clients to slap GLP-1 friendly claims on products
IRE1/XBP1 signaling in tumor growth, angiogenesis, and chemoresistance In parallel to PERK, the IRE1/XBP1 branch of the UPR plays a critical role in sustaining tumor growth and mediating resistance to therapy
If youre dealing with injuries, skin aging, inflammation-related issues, or gut health concerns, KLOW may provide the natural boost you need
Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: a systematic review and meta-analysis of randomized trials
Treatment should not be delayed if neurological symptoms occur, as nerve damage may become irreversible without prompt B12 replacement